Copyright
©2013 Baishideng Publishing Group Co.
World J Hepatol. Jul 27, 2013; 5(7): 387-392
Published online Jul 27, 2013. doi: 10.4254/wjh.v5.i7.387
Published online Jul 27, 2013. doi: 10.4254/wjh.v5.i7.387
No. | Age, yr (at reactivation) | Sex | Disease | Type of IMS | Months from start of IMS to HBV reactivation | Months from last treatment cycle to diagnosis of HBV reactivation | HBV-DNA (IU/mL) at diagnosis of HBV reactivation | ALT/Bil/INR at diagnosis of HBV reactivation | Antiviral treatment | Serology at end of follow-up | Outcome |
1 | 77 | M | NHL | C, Flud, R | 6 | 3 | > 17857000 | 1472/3.22/1.3 | Tenofovir | Anti-HBc (+) | Alive, response1 |
2 | 71 | M | NHL | CHOP-R | 8 | 1 | 487934 | 871/8.8/0.87 | Entecavir | Anti-HBc (+) | Liver related death |
3 | 74 | M | NHL | C, Flud, R | 6 | 1 | 1310000 | 73/0.7/0.97 | Tenofovir | NA | Alive, response1 |
4 | 76 | M | NHL | R | 24 | 1 | > 17857000 | 374/0.44/1.22 | Entecavir | NA | Alive, response1 |
5 | 81 | M | NHL | CHOP-R | 30 | 12 | 660570 | 737/1/1.37 | No treatment due to spontaneous seroconversion | Anti-HBc (+)/anti-HBs (+) 22 IU/L | Alive, response1 |
6 | 78 | M | Castleman’s disease | P, R | 12 | 1 (from last R cycle) | 4228720 | 1536/15.8/1.03 | Lamivudine | Anti HBc (+), anti- HBs (+) 189 IU/L | Non-liver related death |
7 | 82 | M | CLL | Chl, R, C | 22 | 17 (from last R cycle) | > 17857000 | 3440/20.8/1.7 | Tenofovir | HBsAg (+), anti-HBc (+), HBeAg (+) | Alive, response1 |
8 | 72 | M | Temporal arteritis | P, MTX | 6 | 0 | > 17857000 | 308/0.63/1.03 | Tenofovir | NA | Alive, response1 |
9 | 75 | M | Dermatomyositis | P, MTX, AZA, Cyc | 15 | 0 | 126992 | 657/1.47/0.86 | Entecavir | Anti-HBc (+)/anti-HBe (+) | Alive, response1 |
10 | 53 | M | Kidney transplantation | P, Cyc, Myc | 48 | 0 | > 17857000 | 28/0.96/0.98 | Entecavir | HBsAg (+), anti-HBc (+), HBeAg (+) | Alive, response1 |
11 | 73 | F | NHL | CHOP-R | 9 | 4 | 127000 | 614/1.2/1.12 | Lamivudine | Anti-HBc (+) anti-HBs (+) 183 IU/L | Liver related death |
12 | 68 | M | HL | ABVD, CHOP-R, DHAP, HSC transplantation, BEAM | 28 | 16 | > 17857000 | 49/1.1/1.01 | Tenofovir | HBsAg (+), anti-HBc (+), HBeAg(+) | Alive, response1 |
13 | 77 | M | Waldenstrom’s macroglobulinemia | C, R | 36 | 3 (from last R cycle) | > 17857000 | 2500/19/1.19 | Tenofovir | Anti-HBc (+)/anti-HBs (+) 579 IU/mL | Alive, response1 |
14 | 64 | F | RA | MTX, R | 24 | 2 (from last R cycle) | > 17857000 | 72/1.02/0.96 | Entecavir | NA | Alive, response1 |
- Citation: Zachou K, Sarantopoulos A, Gatselis NK, Vassiliadis T, Gabeta S, Stefos A, Saitis A, Boura P, Dalekos GN. Hepatitis B virus reactivation in hepatitis B virus surface antigen negative patients receiving immunosuppression: A hidden threat. World J Hepatol 2013; 5(7): 387-392
- URL: https://www.wjgnet.com/1948-5182/full/v5/i7/387.htm
- DOI: https://dx.doi.org/10.4254/wjh.v5.i7.387